Proteomic analysis of cerebrospinal fluid: Toward the identification of biomarkers for gliomas

Neurosurgical Review

Volumn 37, Issue 3, 2014, Pages 367-380

  Shen, Fang ^a   Zhang, Yang ^b   Yao, Yu ^a   Hua, Wei ^a   Zhang, Hai Shi ^a   Wu, Jing Song ^a   Zhong, Ping ^a   Zhou, Liang Fu ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Biomarker; Central nervous system; Cerebrospinal fluid; Glioma; Proteomics

Indexed keywords

ALBUMIN; ATTRACTIN; BETA 2 MICROGLOBULIN; BETA DEFENSIN; BETA DEFENSIN 106 B; BETA DEFENSIN 107 B; BIOLOGICAL MARKER; CALDESMON; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XII; DIMETHYLARGININASE; FIBROBLAST GROWTH FACTOR 14; GALANIN; GELSOLIN; GLUCOSE REGULATED PROTEIN 78; INTERLEUKIN 6; METHIONYL AMINOPEPTIDASE 2; MYC PROTEIN; OSTEONECTIN; OSTEONECTIN 1; OSTEOPONTIN; PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE A; PREALBUMIN; STAT3 PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN B; WNT4 PROTEIN; TUMOR MARKER;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; COMPUTER MODEL; CYST FLUID; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; GLIOMA; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REVIEW; STRUCTURAL BIOINFORMATICS; SYSTEMATIC REVIEW; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BRAIN NEOPLASMS; CEREBROSPINAL FLUID; METABOLISM; PROGNOSIS;

ANIMALS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM; GLIOMA; HUMANS; PROGNOSIS; PROTEOMICS;

EID: 84904607699     PISSN: 03445607     EISSN: 14372320     Source Type: Journal    
DOI: 10.1007/s10143-014-0539-5     Document Type: Review

References (91)

1. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492-507
2. Patil CG, Yi A, Elramsisy A, Hu J, Mukherjee D, Irvin DK et al (2012) Prognosis of patients with multifocal glioblastoma: a case-control study. J Neurosurg 117:705-711
3. Lawrence YR, Mishra MV, Werner-Wasik M, Andrews DW, Showalter TN, Glass J et al (2012) Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer 118:4228-4234
4. Cancer Genome Atlas Research N (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068
5. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110
6. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462-477
7. Theeler BJ, Yung WK, Fuller GN, De Groot JF (2012) Moving toward molecular classification of diffuse gliomas in adults. Neurology 79:1917-1926
8. Khalil AA (2007) Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci 98:201-213
9. Knorre DG, Kudryashova NV, Godovikova TS (2009) Chemical and functional aspects of posttranslational modification of proteins. Acta Nat 1:29-51
10. Kalinina J, Peng J, Ritchie JC, Van Meir EG (2011) Proteomics of gliomas: initial biomarker discovery and evolution of technology. Neuro Oncol 13:926-942
11. Gromov P, Gromova I, Olsen CJ, Timmermans-Wielenga V, Talman ML, Serizawa RR et al (2013) Tumor interstitial fluid - a treasure trove of cancer biomarkers. Biochim Biophys Acta 1834(11):2259-2270
12. Celis JE, Gromov P, Cabezon T, Moreira JM, Ambartsumian N, Sandelin K et al (2004) Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 3:327-344 (Pubitemid 38702087)
13. Jung CS, Unterberg AW, Hartmann C (2011) Diagnostic markers for glioblastoma. Histol Histopathol 26:1327-1341
14. Seppala TT, Louhija UM, Appelberg B, Herukka SK, Juva K (2013) Comparison Between Clinical Diagnosis and CSF Biomarkers of Alzheimer Disease in Elderly Patients with Late Onset Psychosis: Helsinki Old Age Psychosis Study (HOPS). Am J Geriatr Psychiatry
15. Une K, Takei YA, Tomita N, Asamura T, Ohrui T, Furukawa K et al (2011) Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer 's disease. Eur J Neurol 18:1006-1009
16. Leinonen V, Menon LG, Carroll RS, Dello Iacono D, Grevet J, Jaaskelainen JE et al (2011) Cerebrospinal fluid biomarkers in idiopathic normal pressure hydrocephalus. Int J Alzheimers Dis 2011:312526
17. Jernas M, Malmestrom C, Axelsson M, Olsson C, Nookaew I, Wadenvik H et al (2013) MS risk genes are transcriptionally regulated in CSF leukocytes at relapse. Mult Scler 19:403-410
18. Bartosik-Psujek H, Psujek M, Jaworski J, Stelmasiak Z (2011) Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone. Acta Neurol Scand 123:252-256
19. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L et al (2005) Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 95:1461-1471 (Pubitemid 41779269)
20. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E et al (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9:293-348 (Pubitemid 44253348)
21. Niclou SP, Fack F, Rajcevic U (2010) Glioma proteomics: status and perspectives. J Proteomics 73:1823-1838
22. Nakamizo S, Sasayama T, Shinohara M, Irino Y, Nishiumi S, Nishihara M et al (2013) GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients. J Neuro-oncol 113:65-74
23. Whitin JC, Jang T, Merchant M, Yu TT, Lau K, Recht B et al (2012) Alterations in cerebrospinal fluid proteins in a presymptomatic primary glioma model. PLoS One 7:e49724
24. Shi W, Lv C, Qi J, Zhao W, Wu X, Jing R et al (2012) Prognostic value of free DNA quantification in serum and cerebrospinal fluid in glioma patients. J Mol Neurosci 46:470-475
25. Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zollner H, Schmiegel W et al (2012) Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol 14:29-33
26. Saratsis AM, Yadavilli S, Magge S, Rood BR, Perez J, Hill DA et al (2012) Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid. Neuro Oncol 14:547-560
27. Zheng PP, Luider TM, Pieters R, Avezaat CJ, van den Bent MJ, Sillevis Smitt PA et al (2003) Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 62:855-862 (Pubitemid 37082779)
28. Ohnishi M, Matsumoto T, Nagashio R, Kageyama T, Utsuki S, Oka H et al (2009) Proteomics of tumor-specific proteins in cerebrospinal fluid of patients with astrocytoma: usefulness of gelsolin protein. Pathol Int 59:797-803
29. Schuhmann MU, Zucht HD, Nassimi R, Heine G, Schneekloth CG, Stuerenburg HJ et al (2010) Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur J Surg Oncol 36:201-207
30. Dasgupta B, Yi Y, Hegedus B, Weber JD, Gutmann DH (2005) Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma. Cancer Res 65:9843-9850 (Pubitemid 41541463)
31. Khwaja FW, Reed MS, Olson JJ, Schmotzer BJ, Gillespie GY, Guha A et al (2007) Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 6:559-570 (Pubitemid 46340160)
32. Khwaja FW, Duke-Cohan JS, Brat DJ, Van Meir EG (2006) Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration. Clin Cancer Res 12:6331-6336 (Pubitemid 44799701)
33. Khwaja FW, Nolen JD, Mendrinos SE, Lewis MM, Olson JJ, Pohl J et al (2006) Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 6:6277-6287 (Pubitemid 44935514)
34. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85 (Pubitemid 16258399)
35. Kim YW, Koul D, Kim SH, Lucio-Eterovic AK, Freire PR, Yao J et al (2013) Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro Oncol 15(7):829-839
36. Quezado M, Ronchetti R, Rapkiewicz A, Santi M, Blumenthal DT, Rushing EJ (2005) Chromogenic in situ hybridization accurately identifies EGFR amplification in small cell glioblastoma multiforme, a common subtype of primary GBM. Clin Neuropathol 24:163-169 (Pubitemid 40961500)
37. Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD et al (2009) EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 19:713-723
38. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC et al (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9:469-479 (Pubitemid 29316287)
39. Labussiere M, Sanson M, Idbaih A, Delattre JY (2010) IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? Oncologist 15:196-199
40. Frenel JS, Leux C, Loussouarn D, Le Loupp AG, Leclair F, Aumont M et al (2013) Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. J Neuro-oncol 114(1):85-91
41. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344-350
42. van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW et al (2009) MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 27:5881-5886
43. Faca VM, Hanash SM (2009) In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding. Cancer Res 69:728-730
44. Hondermarck H, Vercoutter-Edouart AS, Revillion F, Lemoine J, el Yazidi-Belkoura I, Nurcombe V et al (2001) Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 1:1216-1232
45. Barderas R, Babel I, Casal JI (2010) Colorectal cancer proteomics, molecular characterization and biomarker discovery. Proteomics Clin Appl 4:159-178
46. Iwadate Y, Sakaida T, Hiwasa T, Nagai Y, Ishikura H, Takiguchi M et al (2004) Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 64:2496-2501 (Pubitemid 38523905)
47. Furuta M, Weil RJ, Vortmeyer AO, Huang S, Lei J, Huang TN et al (2004) Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 23:6806-6814 (Pubitemid 39280012)
48. Li J, Yin C, Okamoto H, Mushlin H, Balgley BM, Lee CS et al (2008) Identification of a novel proliferation-related protein, WHSC1 4a, in human gliomas. Neuro Oncol 10:45-51 (Pubitemid 351250899)
49. Li J, Zhuang Z, Okamoto H, Vortmeyer AO, Park DM, Furuta M et al (2006) Proteomic profiling distinguishes astrocytomas and identifies differential tumor markers. Neurology 66:733-736 (Pubitemid 43739831)
50. Jiang R, Mircean C, Shmulevich I, Cogdell D, Jia Y, Tabus I et al (2006) Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 6:2964-2971 (Pubitemid 43806395)
51. Odreman F, Vindigni M, Gonzales ML, Niccolini B, Candiano G, Zanotti B et al (2005) Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res 4:698-708 (Pubitemid 40863258)
52. Iwadate Y, Sakaida T, Saegusa T, Hiwasa T, Takiguchi M, Fujimoto S et al (2005) Proteome-based identification of molecular markers predicting chemosensitivity to each category of anticancer agents in human gliomas. Int J Oncol 26:993-998
53. Park CK, Jung JH, Park SH, Jung HW, Cho BK (2009) Multifarious proteomic signatures and regional heterogeneity in glioblastomas. J Neuro-oncol 94:31-39
54. Gollapalli K, Ray S, Srivastava R, Renu D, Singh P, Dhali S et al (2012) Investigation of serum proteome alterations in human glioblastoma multiforme. Proteomics 12:2378-2390
55. Xu BJ, An QA, Srinivasa Gowda S, Yan W, Pierce LA, Abel TW et al (2012) Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma. Int J Oncol 40:1995-2003
56. Kumar DM, Thota B, Shinde SV, Prasanna KV, Hegde AS, Arivazhagan A et al (2010) Proteomic identification of haptoglobin alpha2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. J Proteome Res 9:5557-5567
57. Somasundaram K, Nijaguna MB, Kumar DM (2009) Serum proteomics of glioma: methods and applications. Expert Rev Mol Diagn 9:695-707
58. Liu J, Zheng S, Yu JK, Zhang JM, Chen Z (2005) Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B 6:4-10
59. Zhang H, Wu G, Tu H, Huang F (2007) Discovery of serum biomarkers in astrocytoma by SELDI-TOF MS and proteinchip technology. J Neuro-oncol 84:315-323 (Pubitemid 47108522)
60. Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad KS, Sheldon J et al (2008) Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem 54:713-722 (Pubitemid 351573704)
61. Ahn SM, Simpson RJ (2007) Body fluid proteomics: prospects for biomarker discovery. Proteomics Clin Appl 1:1004-1015
62. Kennedy S (2001) Proteomic profiling from human samples: the body fluid alternative. Toxicol Lett 120:379-384
63. Street JM, Barran PE, Mackay CL, Weidt S, Balmforth C, Walsh TS et al (2012) Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl Med 10:5
64. Simonsen AH (2012) Protein profiling of cerebrospinal fluid. Methods Mol Biol 818:109-117
65. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470-1476
66. Tang W, Duke-Cohan JS (2002) Human secreted attractin disrupts neurite formation in differentiating cortical neural cells in vitro. J Neuropathol Exp Neurol 61:767-777 (Pubitemid 35001349)
67. Mayhan WG, Didion SP (1995) Activation of protein kinase C does not participate in disruption of the blood-brain barrier to albumin during acute hypertension. Brain Res 696:106-112
68. Marchi N, Fazio V, Cucullo L, Kight K, Masaryk T, Barnett G et al (2003) Serum transthyretin monomer as a possible marker of blood-to-CSF barrier disruption. J Neurosci 23:1949-1955 (Pubitemid 36314750)
69. Deighton RF, McGregor R, Kemp J, McCulloch J, Whittle IR (2010) Glioma pathophysiology: insights emerging from proteomics. Brain Pathol 20:691-703
70. Patil CG, Nuno M, Elramsisy A, Mukherjee D, Carico C, Dantis J et al (2013) High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era. Neuro Oncol 15:104-111
71. Golan-Gerstl R, Cohen M, Shilo A, Suh SS, Bakacs A, Coppola L et al (2011) Splicing factor hnRNPA2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res 71:4464-4472
72. Katara R, Mir RA, Shukla AA, Tiwari A, Singh N, Chauhan SS (2010) Wild type p53-dependent transcriptional upregulation of cathepsin L expression is mediated by C/EBPα in human glioblastoma cells. Biol Chem 391:1031-1040
73. Brun M, Coles JE, Monckton EA, Glubrecht DD, Bisgrove D, Godbout R (2009) Nuclear factor I regulates brain fatty acid-binding protein and glial fibrillary acidic protein gene expression in malignant glioma cell lines. J Mol Biol 391:282-300
74. Ramao A, Gimenez M, Laure HJ, Izumi C, Vida RC, Oba-Shinjo S et al (2012) Changes in the expression of proteins associated with aerobic glycolysis and cell migration are involved in tumorigenic ability of two glioma cell lines. Proteome Sci 10:53
75. Martinez di Montemuros F, Tavazzi D, Salsano E, Piepoli T, Pollo B, Fiorelli G et al (2001) High frequency of the H63D mutation of the hemochromatosis gene (HFE) in malignant gliomas. Neurology 57:1342 (Pubitemid 32947407)
76. Berger A, Santic R, Almer D, Hauser-Kronberger C, Huemer M, Humpel C et al (2003) Galanin and galanin receptors in human gliomas. Acta Neuropathol 105:555-560 (Pubitemid 36798855)
77. Rolhion C, Penault-Llorca F, Kemeny JL, Lemaire JJ, Jullien C, Labit-Bouvier C et al (2001) Interleukin-6 overexpression as a marker of malignancy in human gliomas. J Neurosurg 94:97-101 (Pubitemid 32799478)
78. Lotz M (1995) Interleukin-6: a comprehensive review. Cancer Treat Res 80:209-233
79. Di Santo E, Alonzi T, Fattori E, Poli V, Ciliberto G, Sironi M et al (1996) Overexpression of interleukin-6 in the central nervous system of transgenic mice increases central but not systemic proinflammatory cytokine production. Brain Res 740:239-244 (Pubitemid 26411305)
80. Stenlof K, Wernstedt I, Fjallman T, Wallenius V, Wallenius K, Jansson JO (2003) Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. J Clin Endocrinol Metab 88:4379-4383 (Pubitemid 37153746)
81. Yeung YT, McDonald KL, Grewal T, Munoz L (2013) Interleukins in glioblastoma pathophysiology: implications for therapy. Br J Pharmacol 168:591-606
82. Qiu B, Zhang D, Wang Y, Ou S, Wang J, Tao J et al (2013) Interleukin-6 is overexpressed and augments invasiveness of human glioma stem cells in vitro. Clin Exp Metastasis 30(8):1009-1018
83. Petrak J, Ivanek R, Toman O, Cmejla R, Cmejlova J, Vyoral D et al (2008) Deja vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 8:1744-1749 (Pubitemid 351678270)
84. Shen G, Liang S, Xu Z, Zhou L, Xiao S, Xia X et al (2010) Downregulated expression of HSP27 in human low-grade glioma tissues discovered by a quantitative proteomic analysis. Proteome Sci 8:17
85. Polisetty RV, Gautam P, Sharma R, Harsha HC, Nair SC, Gupta MK et al (2012) LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signaling and other protein groups of regulatory functions. Mol Cell Proteomics 11(M111):013565
86. Zlobec I, Koelzer VH, Dawson H, Perren A, Lugli A (2013) Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types. J Transl Med 11:104
87. Hamacher M, Marcus K, Stephan C, Klose J, Park YM, Meyer HE (2008) HUPO Brain Proteome Project: toward a code of conduct. Mol Cell Proteomics 7:457 (Pubitemid 351298457)
88. Li CC, Eaton SA, Young PE, Lee M, Shuttleworth R, Humphreys DT et al (2013) Glioma microvesicles carry selectively packaged coding and noncoding RNAs which alter gene expression in recipient cells. RNA Biol 10(8):1333-1344
89. Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringner M et al (2013) Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A 110:7312-7317
90. Bu N, Wu H, Sun B, Zhang G, Zhan S, Zhang R et al (2011) Exosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with glioma. J Neuro-oncol 104:659-667
91. Epple LM, Griffiths SG, Dechkovskaia AM, Dusto NL, White J, Ouellette RJ et al (2012) Medulloblastoma exosome proteomics yield functional roles for extracellular vesicles. PLoS ONE 7:e42064